PharmaPoint: Non-Small Cell Lung Cancer (NSCLC)-Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC)-Global Drug Forecast and Market Analysis to 2025


  • Products Id :- GDHC134PIDR
  • |
  • Pages: 608
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC)-Global Drug Forecast and Market Analysis to 2025

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.

For the purposes of this report, GlobalData considers the Global NSCLC market to include NSCLC-specific drug sales in the 8MM (US, 5EU [France, Germany Italy, Spain, and the UK], Japan, and China). The current market across these countries is dominated by the sale of major chemotherapy regimens, anti-angiogenic agents and targeted therapies for patients with EGFR+ and ALK+ NSCLC. GlobalData estimated that the Global NSCLC market was valued at $6.2b in 2015. The NSCLC therapeutics market is expected to grow at a positive CAGR of 15.7%, reaching 26.71b in the 8MM by 2025.

The growth of the NSCLC market during the forecast period will be driven partly by increasing incident cases of NSCLC in the US, 5EU, Japan, and China, as the population ages. In addition, the launch of premium-priced immuno-oncology (I/O) and targeted pipeline agents will drive the uptake of new therapies and prolong the duration of treatment in the first-line and beyond. The increased used of branded I/O therapies, such as Keytruda, Opdivo, and Tecentriq will be the primary driver of growth during the forecast period. The projected increase in mutation testing rate during the forecast period coupled with the launch of new generation EGFR and ALK TKIs, and BRAF inhibitors will significantly promote the sales of the targeted therapies, Tagrisso, Alecensa, and Tafinlar + Mekinist.

Highlights

Key Questions Answered

Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the NSCLC marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2015-2025)?

What research and development (R&D) strategies will companies leverage to compete in the future NSCLC marketplace?

Which pipeline products are poised to make a major clinical and commercial impact?

What clinical and commercial factors are likely to influence NSCLC drug uptake in the 8MM?

Key Findings

The increasing incorporation of premium-priced immune checkpoint inhibitor immunotherapies into the NSCLC treatment algorithm, particularly in the first-line setting, will be one major driver. Collectively, immunotherapies will reach $17.5B in sales by 2025, accounting for roughly 65% of total sales in the NSCLC market. Of the $17.5B total, Keytruda, Opdivo, and Tecentriq are projected to contribute $5.2B, $5.5B, and $2.8B, respectively.

The increasing incidence of NSCLC in the 8MM will also drive growth. China, in particular, will see its NSCLC incident cases increase dramatically over the forecast period, at an Annual Growth Rate (AGR) of 4.7%. Overall, across the 8MM, the incidence of NSCLC is expected to increase at an AGR of 3.1% from 2015-2025. This increase, coupled with an anticipated increase in branded therapy prescriptions in China, will drive the growth of both the Chinese and global NSCLC markets over the forecast period.

Patent expiration of several blockbuster drugs, including Tarceva and Alimta, and the uptake of generics will limit growth. GlobalData expects sales of the patented drug in the 8MM to decrease from $783M in 2015 to $18M by 2025. In addition, sales of Alimta will decrease from $2.1B in 2015 to $54M in 2025.

An increasing emphasis on cost-consciousness is anticipated over the forecast period, which will limit premium pricing opportunities for developers of NSCLC pipeline agents. GlobalData expects this era of austerity and healthcare reform to make it increasingly more difficult for pharmaceutical companies to gain reimbursement approval for their new NSCLC therapies.

Scope

Overview of NSCLC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.

Topline NSCLC drug market revenue from 2015-2025, annual cost of therapy (ACOT), and major product sales in 17 patient segments during the forecast period are included.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, R&D strategies, and clinical trial mapping for the NSCLC market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NSCLC market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 10

1.1 List of Tables 14

1.2 List of Figures 26

2 Introduction 30

2.1 Catalyst 30

2.2 Related Reports 30

2.3 Upcoming Related Reports 31

3 Disease Overview 32

3.1 Etiology and Pathophysiology 32

3.2 Classification or Staging Systems 36

3.3 Symptoms 39

3.4 Prognosis 40

3.5 Quality of Life 42

4 Epidemiology 43

4.1 Disease Background 43

4.2 Risk Factors and Comorbidities 44

4.3 Global Trends 46

4.4 Forecast Methodology 49

4.5 Epidemiological Forecast for NSCLC (2015-2025)-Base Forecast 72

4.6 Epidemiological Forecast for NSCLC (2015-2025)-Alternate Forecast 86

4.7 Discussion 89

5 Disease Management 92

5.1 Diagnosis and Treatment Overview 92

5.2 US 102

5.3 France 103

5.4 Germany 104

5.5 Italy 105

5.6 Spain 106

5.7 UK 107

5.8 Japan 108

5.9 China 109

6 Competitive Assessment 110

6.1 Overview 110

6.2 Product Profiles-Major Brands, Epidermal Growth Factor Receptor-Targeting 112

6.3 Product Profiles-Major Brands, Anaplastic Lymphoma Kinase-Targeting 160

6.4 Product Profiles-Major Brands, Monoclonal Antibodies 181

6.5 Product Profiles-Major Brands, Other 216

6.6 Chemotherapies 231

7 Unmet Needs Assessment and Opportunity Analysis 233

7.1 Overview 233

7.2 First-Line Treatments That Extend Overall Survival in Advanced-Stage Nonsquamous NSCLC Without Actionable Mutations 235

7.3 Therapies Targeting Novel Biomarkers 238

7.4 Treatment Options for Squamous Patients in the First-Line and Third-Line Setting 242

7.5 Alternative Testing Options for Patients with Insufficient Biopsy Material 247

7.6 Treatments for Patients with Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance 251

8 Pipeline Assessment 256

8.1 Overview 256

8.2 Promising Drugs in Clinical Development 258

8.3 Promising Drugs in Early-Stage Development 423

9 Current and Future Players 447

9.1 Overview 447

9.2 Trends in Corporate Strategy 452

9.3 Company Profiles 455

10 Market Outlook 478

10.1 Global Markets 478

10.2 US 485

10.3 5EU 492

10.4 Japan 499

10.5 China 505

11 Appendix 512

11.1 Bibliography 512

11.2 Abbreviations 558

11.3 Methodology 569

11.4 Forecasting Methodology 569

11.5 Primary Research-KOLs 596

11.6 About the Authors 600

11.7 About GlobalData 603

11.8 Disclaimer 603

1.2 List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages ?18 Years, N, Select Years 2015-2025 77

Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of NSCLC, Both Sexes, N, 2015 80

Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of NSCLC, Ages ?18 Years, N, 2015 82

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of NSCLC, Ages ?18 Years, N, 2015 83

Figure 5: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages ?18 Years, N, Select Years 2015-2025 90

Figure 6: Disease Management Flowchart for nonsquamous NSCLC 102

Figure 7: Disease Management Flowchart for squamous NSCLC 103

Figure 8: Disease Management Flowchart for EGFR+ NSCLC 104

Figure 9: Disease Management Flowchart for ALK+ NSCLC 105

Figure 10: Tarceva's Phase III Development in NSCLC 124

Figure 11: Iressa's Phase II Development in NSCLC 133

Figure 12: Gilotrif's Phase III Development in NSCLC 141

Figure 13: Tagrisso's Phase III Development in NSCLC 148

Figure 14: Portrazza's Phase II Development in NSCLC 155

Figure 15: Conmana's Phase III Development in NSCLC 160

Figure 16: Xalkori's Development in NSCLC 168

Figure 17: Zykadia's Development in NSCLC 176

Figure 18: Alecensa's Development in NSCLC 181

Figure 19: Opdivo's Development in NSCLC 193

Figure 20: Keytruda's Phase III Development in NSCLC 201

Figure 21: Tecentriq's Clincal Development in NSCLC 208

Figure 22: Avastin's Phase III Development in NSCLC 222

Figure 23: Cyramza's Phase III Development in NSCLC 228

Figure 24: Vargatef's Phase II Development in NSCLC 233

Figure 25: NSCLC-Phase II/III Pipeline, 2016, Part I 262

Figure 26: NSCLC-Phase II/III Pipeline, 2016, Part II 263

Figure 27: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2015-2025 264

Figure 28: Yervoy's Clinical Development in NSCLC 268

Figure 29: Clinical and Commercial Positioning of Yervoy 277

Figure 30: Estimated Sales of Ipilimumab Biosimilars Versus Branded Yervoy in NSCLC, 2015-2025 279

Figure 31: Avelumab's Development in NSCLC 282

Figure 32: Clinical and Commercial Positioning of Avelumab 291

Figure 33: Durvalumab's Clinical Development in NSCLC 295

Figure 34: Clinical and Commercial Positioning of Durvalumab 307

Figure 35: Naquotinib's Clincal Development in NSCLC 312

Figure 36: Clinical and Commercial Positioning of Naquotinib 315

Figure 37: Olmutinib's Clincal Development in NSCLC 318

Figure 38: Clinical and Commercial Positioning of Olmutinib 321

Figure 39: Dacomitinib's Clinical Development in NSCLC 324

Figure 40: Clinical and Commercial Positioning of Dacomitinib 330

Figure 41: Ensartinib's Clinical Development in NSCLC 333

Figure 42: Clinical and Commercial Positioning of Ensartinib 338

Figure 43: Brigatinib's Clinical Development in NSCLC 342

Figure 44: Clinical and Commercial Positioning of Brigatinib 347

Figure 45: CimaVax-EGF's Clinical Development in NSCLC 351

Figure 46: Clinical and Commercial Positioning of CimaVax-EGF 355

Figure 47: Tedopi's Clinical Development in NSCLC 358

Figure 48: Clinical and Commercial Positioning of Tedopi 361

Figure 49: Anlotinib's Clinical Development in NSCLC 364

Figure 50: Clinical and Commercial Positioning of Anlotinib 366

Figure 51: Aitan's Clinical Development in NSCLC 368

Figure 52: Clinical and Commercial Positioning of Aitan 370

Figure 53: Fruquintinib's Clinical Development in NSCLC 372

Figure 54: Clinical and Commercial Positioning of Fruquintinib 376

Figure 55: Clinical Development of Avastin Biosimilars in NSCLC 378

Figure 56: Estimated Sales of Bevacizumab Biosimilars Versus Branded Avastin in NSCLC, 2015-2025 380

Figure 57: Abemaciclib's Clinical Development in NSCLC 384

Figure 58: Clinical and Commercial Positioning of Abemaciclib 388

Figure 59: Tafinlar + Mekinist's Clinical Development in NSCLC 392

Figure 60: Clinical and Commercial Positioning of Tafinlar + Mekinist 396

Figure 61: Veliparib's Clinical Development in NSCLC 400

Figure 62: Clinical and Commercial Positioning of Veliparib 405

Figure 63: MM-121's Clinical Development in NSCLC 408

Figure 64: Clinical and Commercial Positioning of MM-121 412

Figure 65: IMMU-132's Clinical Development in NSCLC 415

Figure 66: Clinical and Commercial Positioning of IMMU-132 420

Figure 67: Plinabulin's Clinical Development in NSCLC 423

Figure 68: Clinical and Commercial Positioning of Plinabulin 425

Figure 69: Global Sales of Branded Products for NSCLC by Company, 2015-2025 455

Figure 70: Company Portfolio Gap Analysis in NSCLC, 2015-2025 456

Figure 71: Roche/Genentech SWOT Analysis in NSCLC, 2016 462

Figure 72: Eli Lilly SWOT Analysis in NSCLC, 2016 465

Figure 73: Pfizer SWOT Analysis in NSCLC, 2016 468

Figure 74: AZ SWOT Analysis in NSCLC, 2016 471

Figure 75: BMS SWOT Analysis in NSCLC, 2016 474

Figure 76: Merck & Co. SWOT Analysis in NSCLC, 2016 477

Figure 77: Novartis SWOT Analysis in NSCLC, 2016 479

Figure 78: BI SWOT Analysis in NSCLC, 2016 481

Figure 79: Global Sales for NSCLC (8MM), 2015-2025 483

Figure 80: Global Sales for NSCLC (8MM), 2015-2025 484

Figure 81: Global Sales for NSCLC (8MM), 2015-2025 485

Figure 82: Sales for NSCLC in the US by Drug Class, 2015-2025 491

Figure 83: Sales for NSCLC in the 5EU by Drug Class, 2015-2025 498

Figure 84: Sales for NSCLC in Japan, 2015-2025 504

Figure 85: Sales for NSCLC in urban China by Drug Class, 2015-2025 510

1.1 List of Tables

Table 1: Definitions Used in the AJCC Lung Cancer Staging System 41

Table 2: AJCC Staging of NSCLC 42

Table 3: Symptoms of NSCLC 44

Table 4: Prognostic Factors for NSCLC 45

Table 5: Prognosis for NSCLC Based on Initial Staging 45

Table 6: Risk Factors and Comorbidities for Lung Cancer 49

Table 7: Histological Subtype Distribution Among NSCLC 52

Table 8: 8MM, Relative Survival 53

Table 9: 8MM, Sources Used for Diagnosed Incidence of NSCLC 54

Table 10: 8MM, Sources Used for Cancer Stage at Diagnosis 55

Table 11: 8MM, Sources Used for NSCLC by Histological Subtypes 57

Table 12: US, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation 58

Table 13: 5EU, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation 59

Table 14: Japan, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation 61

Table 15: China (Urban), Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation 62

Table 16: 8MM, Sources Used for Relative Survival of NSCLC 63

Table 17: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages ?18 Years, N, Select Years 2015-2025 77

Table 18: 8MM, Age-Specific Diagnosed Incident Cases of NSCLC, Both Sexes, N (Row %), 2015 79

Table 19: 8MM, Sex-Specific Diagnosed Incident Cases of NSCLC, Ages ?18 Years, N (Row %), 2015 81

Table 20: 8MM, Diagnosed Incident Cases of NSCLC by Clinical Stage at Diagnosis, Ages ?18 Years, N, 2015 84

Table 21: 8MM, Diagnosed Incident Cases of NSCLC by Histological Subtypes, Ages ?18 Years, N, 2015 85

Table 22: 8MM, Mutations Among Diagnosed Incident Cases of ADC, Both Sexes, Ages ?18 Years, N, 2015 86

Table 23: 8MM, Mutations Among Diagnosed Incident Cases of SCC, Both Sexes, Ages ?18 Years, N, 2015 87

Table 24: 8MM, Mutations Among Diagnosed Incident Cases of NSCLC, Both Sexes, N, Ages ?18 Years, 2015 88

Table 25: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages ?18 Years, N, Select Years 2015-2025 89

Table 26: 8MM, Alternate Forecast, Diagnosed Incident Cases of NSCLC by Histology Subtypes, Ages ?18 Years, N, 2015 and 2025 91

Table 27: 8MM, Alternate Forecast, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages ?18 Years, N, Select Years 2015-2025 93

Table 28: Prevalence of Brain and Bone Metastases in NSCLC 97

Table 29: Biomarker Testing Rates in Nonsquamous NSCLC 98

Table 30: Biomarker Testing Rates in Squamous NSCLC 99

Table 31: Treatment Guidelines for NSCLC 100

Table 32: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015-2025 100

Table 33: Country Profile-US 106

Table 34: Country Profile-France 107

Table 35: Country Profile-Germany 108

Table 36: Country Profile-Italy 109

Table 37: Country Profile-Spain 110

Table 38: Country Profile-UK 111

Table 39: Country Profile-Japan 112

Table 40: Country Profile-China 113

Table 41: Leading Treatments for NSCLC, 2016 115

Table 42: Marketed EGFR TKIs in NSCLC 118

Table 43: Product Profile-Tarceva 123

Table 44: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC 127

Table 45: Efficacy of Tarceva in Maintenance Therapy in NSCLC 128

Table 46: Efficacy of Tarceva in Second-and Third-Line Therapy in NSCLC 129

Table 47: Safety of Tarceva 130

Table 48: Tarceva SWOT Analysis, 2016 131

Table 49: Product Profile-Iressa 132

Table 50: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1) 135

Table 51: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2) 135

Table 52: Safety of Iressa 136

Table 53: Iressa SWOT Analysis, 2016 137

Table 54: Product Profile-Gilotrif 139

Table 55: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC 142

Table 56: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC 143

Table 57: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Nave, Squamous NSCLC 143

Table 58: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC 144

Table 59: Safety of Gilotrif 145

Table 60: Gilotrif SWOT Analysis, 2016 146

Table 61: Product Profile-Tagrisso 147

Table 62: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC 150

Table 63: Safety of Tagrisso 151

Table 64: Tagrisso SWOT Analysis, 2016 152

Table 65: Product Profile-Portrazza 154

Table 66: Efficacy of Portrazza in First-Line, Squamous NSCLC 156

Table 67: Safety of Portrazza 157

Table 68: Portrazza SWOT Analysis, 2016 158

Table 69: Efficacy of Conmana in 2L Advanced NSCLC 161

Table 70: Efficacy of Conmana in 1L EGFR-mutant NSCLC 161

Table 71: Safety of Conmana 162

Table 72: Conmana SWOT Analysis, 2016 163

Table 73: Marketed ALK TKIs in NSCLC 164

Table 74: Product Profile-Xalkori 167

Table 75: Efficacy of Xalkori in Treatment-Nave ALK+ Metastatic NSCLC 169

Table 76: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC 170

Table 77: Safety of Xalkori in Treatment-Nave, ALK+ Metastatic NSCLC 172

Table 78: Safety of Xalkori in Previously Treated, Metastatic NSCLC 173

Table 79: Xalkori SWOT Analysis, 2016 174

Table 80: Product Profile-Zykadia 175

Table 81: Efficacy of Zykadia 177

Table 82: Safety of Zykadia 178

Table 83: Zykadia SWOT Analysis, 2016 179

Table 84: Product Profile-Alecensa 180

Table 85: Efficacy of Alecensa 182

Table 86: Efficacy of Alecensa in NSCLC patients with CNS lesions 182

Table 87: Safety of Alecensa 184

Table 88: Alecensa SWOT Analysis, 2016 185

Table 89: Marketed PD-1/PD-L1 ICIs in NSCLC 186

Table 90: Product Profile-Opdivo 191

Table 91: Efficacy of Opdivo in Metastatic Squamous NSCLC 194

Table 92: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC 195

Table 93: Safety of Opdivo 196

Table 94: Opdivo SWOT Analysis, 2016 197

Table 95: Product Profile-Keytruda 199

Table 96: Efficacy of Keytruda 202

Table 97: Safety of Keytruda 203

Table 98: Keytruda SWOT Analysis, 2016 204

Table 99: Product Profile-Tecentriq (atezolizumab) 206

Table 100: Patient Demographics in the Phase II POPLAR Trial (NCT01903993) 209

Table 101: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993) 211

Table 102: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227) 212

Table 103: Patient Demographics in the Phase II FIR Trial (NCT01846416) 213

Table 104: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416) 214

Table 105: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458) 216

Table 106: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993) 217

Table 107: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416) 218

Table 108: Tecentriq SWOT Analysis, 2016 219

Table 109: Product Profile-Avastin 221

Table 110: Efficacy of Avastin in Nonsquamous NSCLC 224

Table 111: Safety of Avastin 225

Table 112: Avastin SWOT Analysis, 2016 225

Table 113: Product Profile-Cyramza 227

Table 114: Efficacy of Cyramza 229

Table 115: Safety of Cyramza 230

Table 116: Cyramza SWOT Analysis, 2016 231

Table 117: Product Profile-Vargatef 232

Table 118: Efficacy of Vargatef in ADC NSCLC 233

Table 119: Safety of Vargatef in ADC NSCLC 234

Table 120: Vargatef SWOT Analysis, 2016 235

Table 121: Summary of Chemotherapies, 2015 236

Table 122: Unmet Need and Opportunity in NSCLC 239

Table 123: Product Profile-Yervoy (ipilimumab) 267

Table 124: Demographics in the Phase II NCT00527735 Trial 269

Table 125: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735) 271

Table 126: Demographics in the Phase I CheckMate 012 Trial (NCT01454102) 272

Table 127: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102) 273

Table 128: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735) 275

Table 129: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102) 276

Table 130: Yervoy SWOT Analysis, 2016 278

Table 131: Product Profile-Avelumab (MSB-0010718C) 281

Table 132: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004) 283

Table 133: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004) 284

Table 134: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC 285

Table 135: Demographics in the Treatment-Nave NSCLC Cohort in the Phase I Trial (NCT01772004) 286

Table 136: Efficacy of Avelumab in Treatment-Nave NSCLC 287

Table 137: Unconfirmed ORR According to PD-L1 Expression in Treatment-Nave NSCLC 288

Table 138: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004) 289

Table 139: Safety of Avelumab in Treatment-Nave NSCLC (NCT01772004) 290

Table 140: Avelumab SWOT Analysis, 2016 292

Table 141: Product Profile-Durvalumab (MEDI4736) 294

Table 142: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial 297

Table 143: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial 298

Table 144: Baseline Characteristics of Patients With Treatment-Nave NSCLC in the Phase I/II 299

Table 145: Efficacy of Durvalumab in Treatment-Nave NSCLC 300

Table 146: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial 301

Table 147: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial 303

Table 148: Safety of Durvalumab in the Phase I/II Trial (NCT01693562) 304

Table 149: Safety of Durvalumab in Treatment-Nave NSCLC 305

Table 150: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial 306

Table 151: Durvalumab SWOT Analysis, 2016 308

Table 152: Product Profile-Naquotinib Mesylate (ASP8273) 312

Table 153: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials 313

Table 154: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients 314

Table 155: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients 315

Table 156: Naquotinib SWOT Analysis, 2016 316

Table 157: Product Profile-Olmutinib (BI 1482694; HM61713) 317

Table 158: Demographics in the Phase I/II NCT01588145 Trial 319

Table 159: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial 320

Table 160: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial 321

Table 161: Olmutinib SWOT Analysis, 2016 322

Table 162: Product Profile-Dacomitinib 324

Table 163: Demographics in the Phase II NCT00818441 Trial 326

Table 164: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial 327

Table 165: Safety of Dacomitinib in Phase II NCT00818441 Trial 329

Table 166: Dacomitinib SWOT Analysis, 2016 330

Table 167: Product Profile-Ensartinib 333

Table 168: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534) 334

Table 169: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534) 335

Table 170: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial 336

Table 171: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534) 337

Table 172: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534) 338

Table 173: Ensartinib SWOT Analysis, 2016 339

Table 174: Product Profile-Brigatinib 341

Table 175: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573) 343

Table 176: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573) 344

Table 177: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases 345

Table 178: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573) 346

Table 179: Brigatinib SWOT Analysis, 2016 347

Table 180: Product Profile-CimaVax-EGF 350

Table 181: Demographics in the Phase III trial of the CimaVax-EGF in Cuba 352

Table 182: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba 353

Table 183: Safety of the CimaVax-EGF in the Phase III Trial in Cuba 354

Table 184: CimaVax-EGF SWOT Analysis, 2016 356

Table 185: Product Profile-Tedopi 358

Table 186: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC 359

Table 187: Efficacy of Tedopi in Advanced NSCLC 360

Table 188: Tedopi SWOT Analysis, 2016 362

Table 189: Product Profile-Anlotinib 364

Table 190: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial 365

Table 191: Anlotinib SWOT Analysis, 2016 366

Table 192: Product Profile-Aitan 368

Table 193: Efficacy of Aitan in Pretreated Nonsquamous NSCLC 369

Table 194: Aitan SWOT Analysis, 2016 370

Table 195: Product Profile-Fruquintinib 372

Table 196: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib 373

Table 197: Efficacy of Fruquintinib in Advanced Solid Tumors 374

Table 198: Safety of Fruquintinib in Advanced Solid Tumors 375

Table 199: Fruquintinib SWOT Analysis, 2016 376

Table 200: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003) 379

Table 201: Product Profile-Abemaciclib 383

Table 202: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016) 385

Table 203: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636) 386

Table 204: Safety of Abemaciclib in Combination with Multiple Single Agents 387

Table 205: Abemaciclib SWOT Analysis, 2016 389

Table 206: Product Profile-Tafinlar + Mekinist 391

Table 207: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634) 393

Table 208: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC 394

Table 209: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC 395

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Roche/Genentech, Eli Lilly, Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Novartis, Boehringer Ingelheim

select a license

Single User License
USD 10995 INR 741613
Site License
USD 21990 INR 1483226
Corporate User License
USD 32985 INR 2224838

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com